Phase 3 Results of Bavarian Nordic’s Smallpox Vaccine Published in The New England Journal of Medicine

    NEXT STORY
    Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai
    PREV STORY
    Curetis Provides Business Update for the First Nine Months of 2019
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

    The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, ...

    author_avatar
    NASDAQ Market News

    Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments

    author_avatar
    NASDAQ Market News

    Catalyst Pharmaceuticals Expands Commercial Leadership Team

    Augments Medical Affairs Team with 3 Additional Medical Science LiaisonsCORAL GABLES, Fla., Aug. 06, ...

    author_avatar
    NASDAQ Market News